Stay updated on Bumetanide Oral Liquid in ASD Children Clinical Trial
Sign up to get notified when there's something new on the Bumetanide Oral Liquid in ASD Children Clinical Trial page.

Latest updates to the Bumetanide Oral Liquid in ASD Children Clinical Trial page
- CheckyesterdayChange DetectedThe record for the bumetanide trial in young children with autism spectrum disorder is available, including its study methods, outcome measures, eligibility criteria, and supporting documents. It reports that the six-month efficacy analysis found no significant difference between bumetanide and placebo.SummaryDifference78%

- Check8 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check22 days agoChange DetectedA notice about NIH website terminology and transition updates appears above the page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record. A Home link is shown, indicating the resource is temporarily unavailable or access-restricted.SummaryDifference19%

- Check57 days agoChange DetectedAdded a new revision label v3.7.0 replacing the previous v3.6.6 in the study record. This reflects an update to the page's versioning metadata rather than substantive changes to the study details.SummaryDifference0.0%

Stay in the know with updates to Bumetanide Oral Liquid in ASD Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bumetanide Oral Liquid in ASD Children Clinical Trial page.